NCT07007312 - Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Biotech Hunter

Enrollment

1,300

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

November 30, 2031

Study Completion Date

November 30, 2031

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Ziftomenib

Oral administration

DRUG

Placebo

Oral administration

DRUG

Venetoclax

Oral administration

DRUG

Azacitidine (AZA)

Intravenous or subcutaneous administration

DRUG

Daunorubicin

Intravenous administration

DRUG

Cytarabine (Ara-C)

Intravenous administration

Trial Locations (2)

RECRUITING

Wayne State University School of Medicine, Detroit

RECRUITING

Yale University School of Medicine, New Haven